Tag: IVL
Shockwave Medical announces US launch of intravascular lithotripsy catheter
Today, Shockwave Medical announced the US launch of its Shockwave Javelin peripheral intravascular lithotripsy (IVL) catheter, a platform designed to modify calcium and cross...
AVS completes US$36 million Series B financing ahead of IVL US...
Amplitude Vascular Systems (AVS) recently announced that it has completed a Series B round of financing of US$36 million. The funding will support the...
FastWave issued seventh utility patent for its IVL portfolio
FastWave Medical has announced the issuance of its seventh utility patent by the US Patent and Trademark Office (USPTO). This patent covers FastWave's laser intravascular...
Boston Scientific to acquire IVL developer Bolt Medical
Boston Scientific has announced it has entered into a definitive agreement to acquire Bolt Medical, the developer of an intravascular lithotripsy (IVL) advanced laser-based...
FastWave Medical closes $19 million financing round to advance IVL portfolio
FastWave Medical has announced the close of a US$19 million funding round earlier this year, increasing the total capital invested into the company to over US$40...
Shockwave Javelin peripheral IVL catheter meets prespecified efficacy and safety performance...
Shockwave Medical, part of Johnson & Johnson MedTech, has announced the first clinical outcomes associated with the Shockwave Javelin peripheral intravascular lithotripsy (IVL) catheter,...
Bolt Medical announces completion of RESTORE ATK and RESTORE BTK pivotal...
Bolt Medical has announced the completion and results of the RESTORE ATK and RESTORE BTK pivotal clinical trials investigating the company's Bolt intravascular lithotripsy...
First patient enrolled in study of integrated laser atherectomy and IVL...
Royal Philips has announced enrolment of the first patient in the US THOR IDE clinical trial, which will study an innovative combined laser atherectomy...
AVS enrols first patient in US pivotal intravascular lithotripsy study
Amplitude Vascular Systems (AVS) recently announced that it has enrolled the first patient in its US pivotal trial for pulsatile intravascular lithotripsy (IVL) therapy....
Shockwave Medical expands US peripheral IVL portfolio with enhanced catheter
Shockwave Medical, part of Johnson & Johnson MedTech, has announced the full US launch of its Shockwave E8 peripheral intravascular lithotripsy (IVL) catheter, following...
CIRSE begins CALCIO trial enrolment for treatment of CLTI with Shockwave...
The Cardiovascular and Interventional Society of Europe (CIRSE) have announced that patient enrolment for the CALCIO trial has begun. CALCIO started patient enrolment on...
AVS receives IDE approval from US FDA for pivotal intravascular lithotripsy...
Amplitude Vascular Systems (AVS) announced today that it has received an investigational device exemption (IDE) from the US Food and Drug Administration (FDA) to...
Johnson & Johnson completes acquisition of Shockwave Medical
Johnson & Johnson today announced it has completed its acquisition of Shockwave Medical. Shockwave is now part of Johnson & Johnson and will operate...
FastWave Medical announces successful 30-day first-in-human data on peripheral IVL technology
FastWave Medical has announced the 30-day results of its first-in-human (FIH) study using the company's differentiated peripheral intravascular lithotripsy (IVL) technology.
This was a...
FastWave Medical announces third utility patent for intravascular lithotripsy technology
FastWave Medical, a clinical-stage medical device company developing intravascular lithotripsy (IVL) technology, has announced the issuance of its third utility patent by the United...
Interventional News’ top 10 most popular stories of April 2023
Several of Interventional News’ most read stories from April covered the topic of interventional oncology (IO)—its interrelation with immuno-oncology, a robot-assisted lung metastases treatment,...
AVS’s pulsatile IVL technology attracts an additional US$8.8 million to close...
AVS, an early-stage medical device company focused on safely and effectively treating severely calcified arterial disease with its pulsatile intravascular lithotripsy (PIVL) therapy, has...
Interventional News’ top 10 most popular stories of March 2023
Interventional News’ most popular stories from March included those covering new embolization and radiofrequency ablation data presented at the Society of Interventional Radiology (SIR)...
Shockwave Medical announces US launch of new peripheral IVL catheter
Shockwave Medical today announced the full US commercial availability of the Shockwave L6 peripheral intravascular lithotripsy (IVL) catheter following clearance by the US Food...
Interventional News’ top 10 most popular stories of January 2023
Interventional News’ most popular stories in the opening month of 2023 included news of first enrolments in clinical studies of peripheral arterial disease (PAD)...
Interventional News Issue 86—June 2022 US Edition
Interventional News 86 Highlights:
Eyes on intravascular lithotripsy
The vascular biology behind endovascular therapies
Profile: Yasuaki Arai
CX: Transfemoral access takes centre stage at...
Interventional News Issue 86—June 2022 Edition
Interventional News 86 Highlights:
Eyes on intravascular lithotripsy
The vascular biology behind endovascular therapies
Profile: Yasuaki Arai
CX: Transfemoral access takes centre stage at...
Shockwave Medical and Genesis MedTech obtain regulatory approval in China for...
Shockwave Medical and Genesis MedTech Group announced today that they have successfully obtained approval from China’s National Medical Products Administration (NMPA) to market and...
Shockwave IVL maintains superiority to angioplasty in calcified peripheral disease at...
Shockwave Medical announced today that long-term data from the Disrupt PAD III trial found that superior vessel preparation with intravascular lithotripsy (IVL) led to...
Shockwave Medical announces global launch of new peripheral IVL catheter
Shockwave Medical has announced the global commercial availability of the Shockwave M5+ peripheral intravascular lithotripsy (IVL) catheter after receiving both CE mark and US...
Shockwave Medical enrols first patient in Disrupt BTK II study for...
Shockwave Medical has announced the start of the Disrupt BTK II postmarket study to assess the safety, effectiveness and optimal clinical use of the...
CMS increases hospital outpatient payment for peripheral intravascular lithotripsy
Shockwave Medical has announced that, as part of the calendar year 2022 Medicare Hospital Outpatient Prospective Payment System (OPPS) final rule, the Centers for...
VIVA 2021: IVL “consistently” treats real-world calcium in multiple peripheral vessel...
An interim analysis from the DISRUPT PAD III observational study showed that intravascular lithotripsy (IVL; Shockwave Medical) performs “consistently well” across challenging peripheral vessels,...
